# EDGAR Filing Document

**Accession Number:** 0001766721
**File Stem:** 0001438934-25-000887
**Filing Date:** 2025-8
**Character Count:** 6032
**Document Hash:** e0a84fc1cc95a48421dba22d702b245e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001438934-25-000887.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0001438934-25-000887

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250818

**EFFECTIVENESS DATE**: 20250818

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aisling Capital Management LP
- **CENTRAL INDEX KEY:** 0001766721

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-19070
- **FILM NUMBER:** 251227017

**BUSINESS ADDRESS:**
- **STREET 1:** 489 5TH AVE, 10TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-651-6380

**MAIL ADDRESS:**
- **STREET 1:** 489 5TH AVE, 10TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001766721

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Aisling Capital Management LP

**Address:** 489 5th Avenue, New York, NY 100017

**Telephone number:** 212-651-6380

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-19070

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER              | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                     | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| ACLARIS THERAPEUTICS, INC.  | 00461U105 | 06/05/2025     | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying the proxy card. | SECTION 14A SAY-ON-PAY VOTES |         434455 |                0 | FOR         |                                   434455 | FOR                         |  |
| BRIDGEBIO PHARMA, INC.      | 10806X102 | 06/20/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                   | SECTION 14A SAY-ON-PAY VOTES |        6068125 |                0 | FOR         |                                  6068125 | FOR                         |  |
| MARKER THERAPEUTICS, INC.   | 57055L206 | 06/06/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                        | SECTION 14A SAY-ON-PAY VOTES |         114285 |                0 | FOR         |                                   114285 | FOR                         |  |
| NUVATION BIO INC.           | 67080N101 | 09/03/2024     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.                    | SECTION 14A SAY-ON-PAY VOTES |        2541009 |                0 | FOR         |                                  2541009 | FOR                         |  |
| NUVATION BIO INC.           | 67080N101 | 05/21/2025     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.                    | SECTION 14A SAY-ON-PAY VOTES |        2541009 |                0 | FOR         |                                  2541009 | FOR                         |  |
| VERONA PHARMA PLC           | 925050106 | 04/24/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.                                          | SECTION 14A SAY-ON-PAY VOTES |         615352 |                0 | FOR         |                                   615352 | FOR                         |  |
| COMPASS PATHWAYS PLC        | 20451W101 | 06/12/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2024.       | SECTION 14A SAY-ON-PAY VOTES |        1198418 |                0 | FOR         |                                  1198418 | FOR                         |  |
| SYNDAX PHARMACEUTICALS, INC | 87164F105 | 05/14/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2025 proxy statement.              | SECTION 14A SAY-ON-PAY VOTES |        1025000 |                0 | FOR         |                                  1025000 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Aisling Capital Management LP

**By (Signature):** Robert Wenzel

**By (Printed Signature):** Robert Wenzel

**By (Title):** CFO

**Date:** 08/15/2025